Department of Pharmaceutical Care, Walailak University, Tha Sala, Nakhon Si Thammarat, 80160, Thailand.
Department of Pharmaceutical Care, Walailak University, Tha Sala, Nakhon Si Thammarat, 80160, Thailand.
Diabetes Metab Syndr. 2022 Mar;16(3):102437. doi: 10.1016/j.dsx.2022.102437. Epub 2022 Feb 28.
This study aimed to assess the effects of vildagliptin on the prevention of cardiovascular diseases in Thai patients with type 2 diabetes mellitus using the Thai Cardiovascular Risk Score.
All patients with type 2 diabetes mellitus who used vildagliptin at a secondary hospital in Thailand were screened and recruited. The relevant variables were obtained from patient medication charts at the first visit on which the patients were prescribed vildagliptin and from the 6-month, 12-month, and 18-month post-treatment visits. The Thai Cardiovascular Risk Score was calculated and monitored as a primary outcome, whereas changes in separate cardiometabolic parameters were assessed as secondary outcomes.
Of the 321 patients screened, only 95 were recruited for the analysis. The average 10-year cardiovascular risks of patients increased from 19.65% at baseline to 20.74%, 20.69%, and 23.78% at 6, 12, and 18 months post treatment, respectively. However, a better trend of reduction in cardiovascular risk was observed in patients with a high baseline cardiovascular risk. The glucose-lowering effects of vildagliptin were significantly observed 12 months of treatment onwards, but non-significant changes were found in lipid and blood pressure levels as well as body mass index.
Vildagliptin provided a promising glucose-lowering effect in Thai patients with type 2 diabetes mellitus. However, the mean 10-year cardiovascular risk did not significantly decrease. However, a negative correlation between cardiovascular risk reduction and baseline cardiovascular risk was observed in this study. Low sample size was a major limitation of this study.
本研究旨在使用泰国心血管风险评分评估维格列汀对泰国 2 型糖尿病患者预防心血管疾病的效果。
筛选了在泰国一家二级医院使用维格列汀的所有 2 型糖尿病患者，并招募了他们。从患者首次就诊时的药物图表以及治疗后 6 个月、12 个月和 18 个月的就诊中获得了相关变量。计算并监测了泰国心血管风险评分作为主要结局，同时评估了单独的心血管代谢参数的变化作为次要结局。
在筛选的 321 名患者中，仅对 95 名患者进行了分析。患者的平均 10 年心血管风险从基线时的 19.65%增加到治疗后 6、12 和 18 个月时的 20.74%、20.69%和 23.78%。然而，在基线心血管风险较高的患者中观察到了更好的心血管风险降低趋势。维格列汀的降血糖作用在治疗 12 个月后显著，但血脂和血压水平以及体重指数的变化不显著。
维格列汀在泰国 2 型糖尿病患者中提供了有前途的降血糖作用。然而，平均 10 年心血管风险并没有显著降低。然而，在本研究中观察到心血管风险降低与基线心血管风险之间存在负相关。样本量小是本研究的主要局限性。
